Curis to Present at Upcoming Investor Conferences

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS),
an oncology-focused company seeking to develop next generation targeted drug
candidates for cancer treatment, today announced that the Company will be
presenting at the following upcoming conferences in New York City:

  oCiti 2013 Global Healthcare Conference – Monday, February 25, 2013 at 3
    p.m. EST. A corresponding audio webcast of this presentation can be
    accessed by visiting:

  oRBC Capital Markets 2013 Healthcare Conference - Tuesday, February 26,
    2013 at 2:05 p.m. A corresponding audio webcast of this presentation can
    be accessed by visiting:

The presentations are scheduled to take place in a fireside chat format in
which Daniel Passeri, President and Chief Executive Officer, will provide a
brief overview of the Company's business strategy and pipeline of small
molecule targeted cancer drug candidates, after which an equity analyst will
moderate a question and answer session.

The audio webcasts will be archived shortly after the live events and
available for 30 days following the conference.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop and
commercialize next generation targeted small molecule drug candidates for
cancer treatment. Erivedge® is the first and only FDA-approved medicine for
the treatment of advanced basal cell carcinoma and is being commercialized and
developed by Roche and Genentech, a member of the Roche Group, under a
collaboration agreement between Curis and Genentech. Curis is also leveraging
its experience in targeting signaling pathways to develop proprietary targeted
cancer programs, including CUDC-427, a small molecule antagonist of IAP
proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information,
visit Curis' website at

The Curis, Inc. logo is available at

CONTACT: For More Information:
         Michael P. Gray
         Chief Financial Officer
         Curis, Inc.

Curis, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.